brahmi

Brahmi (Bacopa monnieri): A Comprehensive Reference

1. Identity, Nomenclature, and Botanical Description

Scientific and Common Names

The plant is known by several names, including brahmi, water hyssop, thyme-leaved gratiola, and the herb of grace. Its accepted scientific binomial is Bacopa monnieri (L.) Wettst. A widely used synonym is Herpestis monniera. The name "brahmi" carries important disambiguation caveats: in southern India, "brahmi" refers to Bacopa monnieri, while in northern India, the same name is commonly applied to Centella asiatica (gotu kola), which also carries the Singhalese name "gotu kola." To further complicate matters, Centella asiatica is synonymous with Hydrocotyle asiatica. The term brahmi has been used to describe Bacopa monnieri, Centella asiatica, or a combination of the two botanicals. In modern scientific and clinical literature, "brahmi" is most consistently used to refer specifically to Bacopa monnieri, and it is under that identity that almost all contemporary pharmacological research has been conducted.

Taxonomy and Physical Description

Bacopa monnieri is a plant used in Ayurveda that belongs to the Scrophulariaceae family and grows naturally in the southeastern regions of Asia, including India, Australia, and Sri Lanka. The plant is characterized by its obovate leaves and small white flowers. Native to the wetlands of India, Southeast Asia, and other tropical regions, this aquatic plant thrives in marshy environments and along riverbanks, where it develops its characteristic thick, succulent leaves rich in bioactive compounds. It grows in a low, sprawling pattern along the ground.

Common Preparations and Dosage Forms

Bacopa is an herbal extract made from the fresh or dried leaves of Bacopa monnieri. Commercially available and clinically studied preparations include standardized dry extracts, capsules, tablets, and liquid tinctures. Forms assessed in clinical trials include crude herb (5 to 10 grams per day, taken in two or three divided doses), a 1:5 tincture (10 to 20 mL per day, taken in two or three divided doses), and standardized extract (300 to 450 mg per day). The most common dose for Bacopa monnieri in research settings is 300 mg per day, assuming that the total bacoside content (the active compound) is approximately 55% of the extract by weight. In Ayurvedic practice, the herb is also used as a component of compound formulations such as ghee (ghrita) preparations and medicated oils.

2. Traditional and Historical Use

Ayurvedic Tradition

Bacopa monnieri is a plant that has been used for approximately 5,000 years in Ayurveda, the traditional Indian medicine. In the Charaka Samhita, which describes Ayurvedic culture, Bacopa is presented as a plant for treating various mental disorders and is referred to as "medhya rasayana," which translates to "rejuvenating herbs" believed to enhance memory, mental health, and intellect, as well as to promote long life and rejuvenation. Its name "Brahmi" is derived from Lord Brahma, the creator god of the Hindu pantheon of deities, and it finds special mention in Ayurvedic literature for its use in different mental conditions such as anxiety, poor cognitive abilities, and lack of concentration.

The main indications for using Bacopa in Ayurvedic medicine are memory improvement, insomnia, epilepsy, and as an anxiolytic. Ancient practitioners in Vedic times recommended brahmi for students preparing for exams, scholars reciting long verses, and monks engaged in deep meditation. In Kerala's traditional Ayurveda, brahmi leaves were crushed into a paste for topical relief of ulcers and minor wounds, while decoctions or ghrita (ghee-based formulations) targeted nervous exhaustion and anxiety. The Charaka Samhita describes brahmi ghrita — a medicated clarified butter preparation — for cognitive enhancement and medhya (intellect-promoting) purposes.

Use in Other Traditional Systems

Across Southeast Asia and in traditional Unani medicine of Persia, Bacopa monnieri was similarly valued for boosting memory and alleviating mental fatigue. Beyond India, traces of Bacopa use can also be found in China and other systems of traditional oriental medicine. Bacopa monnieri has been used for centuries in Ayurvedic medicine, alone or in combination with other herbs, as a memory and learning enhancer, sedative, and anti-epileptic.

3. Key Constituents and Active Compounds

Primary Bioactive Class: Bacosides

The best-characterized phytochemicals in Bacopa monnieri are dammarane-type triterpenoid saponins known as bacosides, with jujubogenin or pseudo-jujubogenin moieties as aglycone units. Bacosides comprise a family of 12 known analogs. Other saponins called bacopasides I–XII have also been identified. The aglycone unit in triterpenoid saponins is either jujubogenin or pseudojujubogenin, isomers with prenyl side chains substituted at C-23 and C-22 positions, respectively. Most glycosides have sugar chains attached to the C-3 only (classified as monodesmosides), and in a few to both C-3 and C-20 positions (classified as bidesmosides) of the aglycone unit.

Bacosides are significant components of Bacopa monnieri and play essential roles in neuronal health. Structurally, bacoside A (PubChem ID: 92043183) is an amphiphilic chemical compound containing both sterol and sugar moieties. HPLC-based studies have quantified individual components of bacoside A: bacoside A3 ranged from 0.14% to 0.85%, and bacopaside II from 0.12% to 0.69%, reflecting regional variation in the plant material.

Other Phytochemical Constituents

Analytical studies demonstrate that B. monnieri possesses a diverse chemical composition consisting of bacosides, bacopasides, bacopasaponins, apigenin, cucurbitacin, brahmine, monnierin, hersaponin, monnierasides, d-mannitol, herpestin, and nicotine. Biochemical studies have identified additional pharmacological compounds from ethanolic extracts, including alkaloids (brahmine, nicotine, and herpestine), saponins (monnierin, hersaponin), sterols (β-sitosterol, stigmasterol), d-mannitol, acid A, and betulinic acid. Active compounds of note include bacosides A and B, betulinic acid, loliolide, asiatic acid, and quercetin. The primary alkaloid, brahmine, is believed to contribute to neuroprotective effects.

Blood-Brain Barrier Penetration

Bacosides, which are nonpolar glycosides, can cross the blood-brain barrier via simple lipid-mediated passive diffusion. This pharmacokinetic property is considered relevant to their observed central nervous system effects.

4. Established and Proposed Mechanisms of Action

Current evidence suggests Bacopa monnieri acts via the following mechanisms: antioxidant neuroprotection (via redox and enzyme induction), acetylcholinesterase inhibition and/or choline acetyltransferase activation, β-amyloid reduction, increased cerebral blood flow, and neurotransmitter modulation including acetylcholine (ACh), 5-hydroxytryptamine (5-HT), and dopamine (DA).

The neuroprotective mechanism of B. monnieri is mainly discussed on the basis of antioxidant activity, inhibition of acetylcholinesterase activity, promotion of choline acetyltransferase activity, anti-inflammatory activity, intellectual enhancing activity, beta-amyloid reduction activity, neurotransmitter modulation activity, and cerebral blood flow enhancing activity.

Possible mechanisms leading to cognitive improvement include modulation of acetylcholine release, muscarinic cholinergic receptor binding, and choline acetylase activity. The saponins in Bacopa also modulate hypothalamic-pituitary-adrenal axis output and protect the hippocampus.

Bacopa primarily either acts via antioxidant mechanism (neuroprotection) or alters neurotransmitters — serotonin (5-HT), dopamine (DA), acetylcholine (ACh), and GABA — to execute the pharmacological effect. Among these, 5-HT has been shown to fine-tune neural plasticity, which is a substrate for memory formation.

Foremost among its neuroprotective actions is potent antioxidant activity, which mitigates oxidative stress by neutralizing reactive oxygen species and inhibiting lipid peroxidation, thereby preserving neuronal integrity.

Bacopa also causes an anti-inflammatory effect on activated microglial cell cultures. Metabolites or active compounds from B. monnieri interact with the dopamine and serotonergic systems, and the plant's main molecular mechanism concerns promoting neuron communication by increasing the growth of nerve endings (dendrites).

It must be noted that the majority of mechanistic evidence derives from in vitro cell culture and animal studies. Numerous animal and in vitro studies have been conducted, with many evidencing potential medicinal properties. Direct confirmation of these mechanisms in human subjects at clinically used doses remains limited.

5. Scientific Evidence by Area of Use

5.1 Cognitive Function and Memory in Healthy Adults

Many clinical studies have demonstrated improvements in verbal learning, delayed word recall, memory acquisition, and anxiety reduction with using Bacopa. It has been described as a calming cognitive enhancer.

A key 2012 systematic review (Pase et al., published in the Journal of Alternative and Complementary Medicine) evaluated the human clinical evidence. Six studies met the final inclusion criteria and were included in review. Trials were all conducted over 12 weeks. Across trials, three different Bacopa extracts were used at dosages of 300–450 mg extract per day. Research into the nootropic effects of Bacopa was described as being in its infancy, with research yet to investigate Bacopa's effects across all human cognitive abilities; future research was indicated to examine nootropic effects at varied dosages and across different extracts.

A subsequent 2014 meta-analysis of randomized controlled trials (Kongkeaw et al., published in the Journal of Ethnopharmacology) found that the systematic review and meta-analysis of randomized, controlled trials demonstrated that Bacopa monnieri extract has the potential to improve cognitive performance, particularly speed of attention by reducing choice reaction time. This meta-analysis included randomized, placebo-controlled human intervention trials on chronic (≥12 weeks) dosing of standardized extracts of Bacopa monnieri without any co-medication.

A notable randomized, double-blind, placebo-controlled trial by Calabrese et al. (2008), published in the Journal of Alternative and Complementary Medicine, evaluated effects in healthy elderly subjects. The study aimed to evaluate effects of Bacopa monnieri whole plant standardized dry extract on cognitive function and affect, and its safety and tolerability in healthy elderly study participants. The study was a randomized, double-blind, placebo-controlled clinical trial with a placebo run-in of 6 weeks and a treatment period of 12 weeks. Controlling for baseline cognitive deficit, Bacopa participants had enhanced AVLT delayed word recall memory scores relative to placebo. Stroop test results were similarly significant, with the Bacopa group improving and the placebo group unchanged. CESD-10 depression scores, combined state plus trait anxiety scores, and heart rate decreased over time for the Bacopa group but increased for the placebo group. No effects were found on the Divided Attention Task, WAIS digit task, mood, or blood pressure. The dose was well tolerated, with few adverse events primarily involving stomach upset.

Evidence strength: The body of evidence in healthy adults is consistent in showing effects on delayed word recall and speed of processing over 12-week periods, but individual trials have been small in size. The evidence base supports modest, time-dependent cognitive benefits from standardized extracts, particularly for memory, but the number and scale of trials remain limited. Results across different cognitive domains are uneven.

5.2 Cognitive Function in Older Adults and Age-Related Decline

BM has anti-apoptotic and antioxidant actions and can repair damaged neurons, stimulate kinase activity, restore synaptic function, improve nerve transmission, and increase neuroprotection. A systematic review including twenty-two clinical trials demonstrated that BM can reduce Nuclear Factor-κB phosphorylation, improve emotional function, cognitive functions, anhedonia, hyperactivity, sleep routine, depression, attention deficit, learning problems, memory retention, impulsivity, and psychiatric problems.

One trial provided further evidence that B. monnieri has potential for safely enhancing cognitive performance in aging individuals.

Evidence strength: Promising but preliminary. Most trials in this population are small, and the most rigorously conducted trials have produced mixed results across cognitive domains. Large-scale adequately powered trials in older adults are lacking.

5.3 Alzheimer's Disease and Dementia

Bacopa monnieri has shown neuroprotective effects in animal and in vitro studies; however, human studies on patients with Alzheimer's disease have been inconclusive. There is also evidence for potential attenuation of dementia, Parkinson's disease, and epilepsy, though this largely comes from animal studies.

In vitro and in vivo studies suggest that bacosides have anxiolytic, anti-inflammatory, antioxidant, antiulcer, and neuroprotective properties leading to purported effects in dementia, hyperactivity, memory loss, and depression. However, Bacopa has not been shown to be effective for any disease or medical symptom in adequately controlled, prospective trials in humans.

Evidence strength: Insufficient for a clinical recommendation. Mechanistic and preclinical evidence is substantial, but high-quality human RCT evidence for Alzheimer's disease specifically is lacking.

5.4 Anxiety and Mood

The main traditional indications for using Bacopa in Ayurvedic medicine include its use as an anxiolytic. The 2008 Calabrese et al. trial found that combined state plus trait anxiety scores decreased over time for the Bacopa group but increased for the placebo group.

An early clinical trial cited in the patent literature reported that administration of Brahmi syrup equivalent to 12 g dry crude extract to 35 patients with diagnosed anxiety neurosis resulted in a significant decrease in anxiety symptoms, level of anxiety, level of disability, and mental fatigue, and exhibited considerable increase in immediate memory span.

Evidence strength: Preliminary positive signals in small trials, but the evidence base for anxiety as a primary indication is not robust. Most trials have assessed anxiety as a secondary outcome measure.

5.5 Attention-Deficit/Hyperactivity Disorder (ADHD) in Children

The plant has been studied for its potential in treating ADHD. In one study, children were given a dose of 225 mg per day for 6 months, which proved not only safe but also effective in eliminating ADHD symptoms in children.

Among 93 male children, ages 6 to 14, with inattention or hyperactivity treated with Bacopa monnieri or placebo for 14 weeks, there were minor differences in various measures of cognitive function and mood, but no differences in behavioral outcomes and no serious adverse events; 3 children receiving the herbal preparation complained of short-lived gastrointestinal discomfort.

A systematic review by Kean et al. (2017, published in PMC) investigated poly-herbal formulas containing B. monnieri in children and adolescents. Nine trials met inclusion criteria; five studies reported sufficient data for effect size analysis, with most improvements reported in behavioral outcomes.

Evidence strength: Weak to preliminary. Available trials are small, use heterogeneous formulations, and produce inconsistent behavioral results. This remains an area requiring further large-scale controlled research.

5.6 Other Pharmacological Areas (Preclinical and Early-Stage Evidence)

Bacopa monnieri has many pharmacological actions, including antioxidant, anti-inflammatory, anticonvulsant, cardiotonic, bronchodilator, and peptic ulcer protection. It possesses pharmacological activities such as antioxidant, gastrointestinal, endocrine, antimicrobial, and anti-inflammatory effects. Extract is reported to possess relaxant property in tracheal muscle and is also helpful in producing bronchodilation.

These areas, while mechanistically plausible and supported by animal data, lack human clinical trial evidence sufficient for establishing efficacy.

6. Body Systems Associated with Brahmi

• Central Nervous System: Bacopa monnieri shows great potential for multi-targeted activity, primarily due to its rich profile of bioactive compounds. It is particularly renowned for its impact on the nervous system, exhibiting neuroprotective effects on multiple levels of neural functioning and across various neurodegenerative pathways.
• Endocrine / Thyroid: Animal research suggests Bacopa may increase thyroxine levels (T4) in mice by about 40%. It should be used cautiously (or avoided) in those with a thyroid condition or who take thyroid hormone medications.
• Gastrointestinal System: Bacopa possesses gastrointestinal pharmacological activity, and multiple clinical trials have recorded gastrointestinal symptoms as adverse events (see Safety section).
• Cardiovascular: Cardiotonic activity has been documented in animal research.
• Respiratory: Relaxant and bronchodilatory properties have been reported in animal/in vitro models.
• Liver (Hepatoprotective): The milieu of nootropic phytochemicals within BM exhibit minimal observable adverse effects at standard dosages, and BM demonstrates antioxidant and hepatoprotective activity.

7. Dosage: Forms and Quantities Reported in Studies

The typical dose reported in the literature is 300 to 600 mg of the extract daily, equivalent to 5 to 10 grams of the dried herb. Across the six trials included in the Pase et al. (2012) systematic review, trials were all conducted over 12 weeks; three different Bacopa extracts were used at dosages of 300–450 mg extract per day.

The most commonly studied dose is 300 mg per day, assuming total bacoside content of approximately 55% of the extract by weight. In the ADHD pediatric study, children were given a dose of 225 mg per day for 6 months.

Doses of 30, 60, 300, and 1,500 mg/kg/day of Bacopa monnieri extract were used for chronic toxicity testing in animals. A clinical study conducted on 23 volunteers showed no alarming changes indicating toxicity of a preparation containing Bacopa monnieri; each participant received a 300 mg tablet and a 450 mg tablet for 30 days, with each dose consumed for 15 days.

Notably, the commercially studied extracts include proprietary standardized preparations. Some studies have used formulations such as BacoMind, Keen-Mind, and CDRI-08. Standardization of these products varies, and not all commercial preparations are identical to those tested in clinical trials.

8. Safety Considerations and Drug Interactions

General Tolerability

Bacopa has a high therapeutic index and is generally well-tolerated. The most common side effects are gastrointestinal, including increased stool frequency, nausea, and abdominal cramps. Other reported side effects may include abdominal pain, diarrhea, flatulence, dry mouth, headache, dizziness, insomnia, and rash. In small clinical trials, Bacopa was reported to be safe for healthy adults when used for three months.

Concerning safety, Bacopa monnieri has been found to be generally non-toxic, with no serious side effects reported. However, interactions with certain medications and contraindications in conditions like hyperthyroidism should be considered. Further research is needed to determine optimal dosages and ensure safety, especially for pregnant and breastfeeding women.

Liver Safety

There is no evidence to indicate that Bacopa monnieri causes liver injury despite the fact that it has multiple ingredients including triterpenoid bacopa saponins and saponin glycosides. Bacopa has not been linked to liver enzyme elevations during therapy nor to instances of clinically apparent acute liver injury. Animal studies corroborate this: rats treated with B. monnieri showed no significant histological changes in any internal organs, including the kidneys and liver, at doses of 30, 60, 300, and 1,500 mg/kg/day administered for 270 days, with no significant changes indicating toxicity of the extract.

Thyroid Interactions

Animal research suggests Bacopa may increase thyroxine levels (T4) in mice by about 40%; it should therefore be used cautiously (or avoided) in those with a thyroid condition or who take thyroid hormone medications. Contraindications in conditions like hyperthyroidism should be considered.

Cholinergic System Interactions

Bacopa could counteract the effects of anticholinergic drugs and may worsen bradycardia and exacerbate conditions such as gastrointestinal obstruction, peptic ulcer disease, pulmonary conditions such as asthma and chronic obstructive pulmonary disease, or urogenital tract obstruction. Because of its acetylcholinesterase-inhibiting function, high acetylcholine levels may lead to bradycardia, so individuals predisposed to slow heart rates should be aware of this risk.

Bacopa may affect thyroid hormone levels or modulate the cholinergic system. Therefore, people who take thyroid drugs or drugs that affect cholinergic pathways (e.g., acetylcholinesterase inhibitors or cholinergic drugs) should be cautious.

Cytochrome P450 (CYP) Enzyme Inhibition

Bacopa has been shown to inhibit human cytochrome P450 enzymes, which could contribute to herb-drug interactions when co-administered orally with medications metabolized by CYP1A2, CYP2C9, CYP3A4, and CYP2C19. B. monnieri extract exhibited non-competitive inhibition of CYP2C19, CYP2C9, and CYP1A2, and competitive inhibition of CYP3A4 in vitro. However, the isolated bacosides showed negligible inhibition of the same isoforms, suggesting that other constituents in the whole extract contribute to this inhibition. Since B. monnieri is orally administered, it has a higher concentration in the gut than the liver; at an estimated gut concentration of 600 µg/mL based on a daily dosage of 300 mg/day, B. monnieri reduced the catalytic activities of CYP3A4, CYP2C9 and CYP2C19 to less than 10% compared to total activity. The clinical significance of these in vitro findings has not been fully characterized in human pharmacokinetic studies.

Galantamine Interaction

Early studies suggest that the concomitant use of Bacopa monnieri and galantamine may have a synergistic effect on cognitive function, though there is a need for further research into the potential risk of side effects and pharmacodynamic interactions.

Pregnancy and Breastfeeding

Further research is needed to determine optimal dosages and ensure safety, especially for pregnant and breastfeeding women. The safety profile in these populations has not been established in controlled human studies.

References

• Walker EA, Pellegrini MV. Bacopa monnieri. In: StatPearls [Internet]. NCBI Bookshelf / StatPearls Publishing, 2023.
• Bacopa monnieri. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, NIH. Updated April 2024.
• Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647–652.
• Kongkeaw C et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–535. [DARE Review, NCBI Bookshelf]
• Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313–326. PMC3746283.
• Stough C et al. Mechanisms, Efficacy, and Safety of Bacopa monnieri (Brahmi) for Cognitive and Brain Enhancement. Evid Based Complement Alternat Med. 2015. PMC4568033.
• Rajan KE et al. Molecular and Functional Characterization of Bacopa monniera: A Retrospective Review. Evid Based Complement Alternat Med. 2015. PMC4564644.
• Calabrese C et al. Effects of a Standardized Bacopa monnieri Extract on Cognitive Performance, Anxiety, and Depression in the Elderly. J Altern Complement Med. 2008;14(6):707–713. PMC3153866.
• Kean JD et al. Systematic Overview of Bacopa monnieri (L.) Wettst. Dominant Poly-Herbal Formulas in Children and Adolescents. Medicines. 2017. PMC5750610.
• Hristov M et al. Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis. Antioxidants. 2024;13(4):393. PMC11047749.
• Gościniak A et al. Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability. Nutrients. 2025;17(11):1939. PMC12158153.
• Ramasamy S et al. Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents. J Ethnopharmacol. 2019. PMC6271976.
• Fatima U et al. Pharmacological attributes of Bacopa monnieri extract: Current updates and clinical manifestation. Front Nutr. 2022. PMC9436272.
• Tiwari S et al. In Vitro Propagation, Phytochemical and Neuropharmacological Profiles of Bacopa monnieri (L.) Wettst.: A Review. Evid Based Complement Alternat Med. 2020. PMC7238420.
• Bhandari P, Sendri N, Devidas SB. Dammarane triterpenoid glycosides in Bacopa monnieri: A review on chemical diversity and bioactivity. Phytochemistry. 2020;172:112276.
• Basheer A et al. Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials. Interact J Med Res. 2022;11(2):e38542.
• Alzheimer's Drug Discovery Foundation. Bacopa monnieri & Your Brain. Cognitive Vitality.
• Examine.com. Bacopa monnieri benefits, dosage, and side effects. Examine.
• Bacopa monnieri – an overview. ScienceDirect Topics.